CD274 and cancer: Among the various immunotherapeutic strategies, immune checkpoint inhibitors, such as antibodies against CTLA-4, PD-1, or its ligand PD-L1, have been proven successful in the treatment of several types of cancer.10 These immune checkpoint antibodies interrupt immune resistance mechanisms exploited by tumours to evade natural anti-tumour T-cell immunity.